Table 1 Patient demographics and clinical characteristics at baseline and BOR per INV for all treated, WES-evaluable, RNA-seq–evaluable and CD3 IHC-evaluable patients
All treated (n = 193) | WES-evaluable (n = 59) | RNA-seq–evaluable (n = 57) | CD3 IHC-evaluable (n = 59) | |
|---|---|---|---|---|
Median age (range), years | 56 (21‒88) | 62 (31‒88) | 62 (31‒88) | 55 (27‒81) |
Sex, n (%) | ||||
Male | 114 (59) | 30 (51) | 29 (51) | 31 (53) |
Female | 79 (41) | 29 (49) | 28 (49) | 28 (47) |
ECOG performance status,a n (%) | ||||
0 | 86 (45) | 32 (54) | 31 (54) | 23 (39) |
1 | 106 (55) | 27 (46) | 26 (46) | 36 (61) |
Disease stage at diagnosis,b n (%) | ||||
Stage I–III | 107 (55) | 33 (56) | 33 (58) | 29 (49) |
Stage IV | 86 (45) | 26 (44) | 24 (42) | 30 (51) |
Primary tumor location, n (%) | ||||
Colon NOS | 3 (2) | 2 (3) | 2 (4) | 0 |
Left-sided | 60 (31) | 25 (42) | 24 (42) | 19 (32) |
Right-sided | 130 (67) | 32 (54) | 31 (54) | 40 (68) |
Mutation status, n (%) | ||||
BRAF/KRAS wild type | 60 (31) | 15 (25) | 15 (26) | 17 (29) |
BRAF mutation | 42 (22) | 11 (19) | 11 (19) | 9 (15) |
KRAS mutation | 71 (37) | 27 (46) | 25 (44) | 24 (41) |
Unknown | 20 (10) | 6 (10) | 6 (11) | 9 (15) |
Clinical history of Lynch syndrome, n (%) | ||||
Yes | 65 (34) | 8 (14) | 9 (16) | 22 (37) |
No | 74 (38) | 28 (47) | 27 (47) | 28 (47) |
Unknown | 54 (28) | 23 (39) | 21 (37) | 9 (15) |
BOR per INV, n (%) | ||||
CR | 32 (17) | 8 (14) | 8 (14) | 9 (15) |
PR | 74 (38) | 26 (44) | 24 (42) | 19 (32) |
SD | 47 (24) | 11 (19) | 12 (21) | 14 (24) |
PD | 33 (17) | 11 (19) | 11 (19) | 13 (22) |
NE | 7 (4) | 3 (5) | 2 (4) | 4 (7) |
